Martel Pierre, Capdet Jérôme, Méry Eliane, Zerdoud Slimane, Ferron Gwénaël, Rafii Arash, Roché Henri, Querleu Denis
Département de chirurgie, Institut Claudius-Regaud, 20-24, rue du Pont-Saint-Pierre, 31052 Toulouse, France.
Bull Cancer. 2008 Jul-Aug;95(7):763-72. doi: 10.1684/bdc.2008.0640.
Identification of sentinel node (SN) involvement predictive factors, non-sentinel node involvement predictive factors, selective prognosis of each group of patients by study of breast surgery cases with sentinel node sampling.
Prospective monocentric registering of 993 sentinel node samples routinely taken between January 2001 and October 2005, covering technical aspects of detection (colorimetric and radio-isotope), pathological results (serial sections 5 Mmicro thick prior to staining hematoxylin-eosine-saffron and if necessary, by immune histochemistry cytokeratine high molecular weight), therapeutics and follow-up (average period: 32 months (3-69).
Seven hundred and sixteen patients (72.1%) were free of sentinel node involvement. Among positive sentinel node patients (27.9%), 14.5% presented macrometastasis, 11% micrometastasis and 2.4% isolated tumor cells (CTI). Sentinel node involvement risk factors included: related to clinical features, age (2 years younger in the micrometastatic group compared to the macrometastatic group); related to tumor caracteristics, size (12.15 mm for the negative SN group, 15.4 mm for the micrometastatic group and 16.25 mm for the macrometastatic group), grading (a majority of grade I encountered with micrometastasis versus macrometastasis) and multifocality (macrometastasis SN associated with multilocular tumor in 77.8% cases, micro metastasis SN in 22.2% cases and negative SN in 6.7% cases). Predictive factors do not differ for micro- or macrometastasic involvement. Among features concerning secondary axillary dissection, 47.1% (66/140) were positive with a macrometastatic SN, 12.1% (13/107) with micrometastic SN. Predictive factors of positive secondary axillary dissection were tumor size, grading, micrometastasis size and micrometastasis multifocality. With a 32 months mean follow-up, the positive micrometastasis sub-group (with or without positive secondary axillary dissection) expressed one only metastatic recurrence (0.9%); on the contrary, three patients (2.1%) issued from the macrometastatic SN group, expressed metastatic recurrence. One only local axillary recurrence (0.14%) occurred among negative SN (717 cases); no axillary recurrence occurred among the 30 patients without secondary axillary dissection (CTI [22 cases], micrometastatic SN group [5 cases] and macrometastatc group [3 cases]).
First, 72.1% of T0 or T1 tumors, avoid adverse axillary dissection effects. Second, micrometastatic involvement predictive factors do not differ from macrometastatic ones and those of positive secondary axillary dissection among micrometastatic SN do not appear clearly : the risk of axillary recurrence is low: at the very most, it seems possible to propose a safe guideline, avoiding secondary axillary dissection only for selected group of lower risk patients: tumoral size < 10 mm, grade I, monocentric SN involvement. Third, it is not possible to differentiate a selective prognosis between negative, CTI, micrometastatic and macrometastatic SN subgroups probably because of a short follow-up. Fourth, teaching through companionship is fully valided by the secondary minimal rate of axillary recurrence.
通过对前哨淋巴结取样的乳腺癌手术病例进行研究,确定前哨淋巴结受累的预测因素、非前哨淋巴结受累的预测因素以及每组患者的选择性预后。
对2001年1月至2005年10月期间常规采集的993个前哨淋巴结样本进行前瞻性单中心登记,涵盖检测技术方面(比色法和放射性同位素法)、病理结果(苏木精 - 伊红 - 番红染色前5微米厚的连续切片,必要时通过免疫组织化学检测高分子量细胞角蛋白)、治疗方法和随访情况(平均随访期:32个月(3 - 69个月))。
716例患者(72.1%)前哨淋巴结未受累。在前哨淋巴结阳性的患者中(27.9%),14.5%出现大转移灶,11%出现微转移灶,2.4%出现孤立肿瘤细胞(CTI)。前哨淋巴结受累的危险因素包括:与临床特征相关的年龄(微转移组比大转移组年轻2岁);与肿瘤特征相关的大小(前哨淋巴结阴性组为12.15毫米,微转移组为15.4毫米,大转移组为16.25毫米)、分级(微转移灶中I级占多数,与大转移灶情况不同)和多灶性(大转移灶的前哨淋巴结与多房性肿瘤相关的病例占77.8%,微转移灶的前哨淋巴结相关病例占22.2%,前哨淋巴结阴性相关病例占6.7%)。微转移或大转移受累的预测因素无差异。在关于腋窝二次清扫的特征中,前哨淋巴结大转移的患者中47.1%(66/140)腋窝二次清扫为阳性,前哨淋巴结微转移的患者中12.1%(13/107)腋窝二次清扫为阳性。腋窝二次清扫阳性的预测因素为肿瘤大小、分级、微转移灶大小和微转移灶多灶性。平均随访32个月,微转移阳性亚组(无论腋窝二次清扫是否阳性)仅出现1例转移复发(0.9%);相反,前哨淋巴结大转移组有3例患者(2.1%)出现转移复发。前哨淋巴结阴性的717例患者中仅发生1例腋窝局部复发(0.14%);30例未进行腋窝二次清扫的患者(CTI组[22例]、微转移灶前哨淋巴结组[5例]和大转移灶组[3例])未发生腋窝复发。
第一,72.1%的T0或T1期肿瘤患者可避免腋窝清扫的不良影响。第二,微转移受累的预测因素与大转移的预测因素无差异,微转移前哨淋巴结患者腋窝二次清扫阳性的预测因素不明显:腋窝复发风险较低:最多,似乎有可能提出一个安全的指导原则,仅对低风险患者的特定组避免进行腋窝二次清扫:肿瘤大小<10毫米、I级、单中心前哨淋巴结受累。第三,可能由于随访时间短,无法在前哨淋巴结阴性、CTI、微转移和大转移亚组之间区分选择性预后。第四,通过陪伴教学在腋窝复发的二次最低发生率方面得到了充分验证。